As several siRNA assets indicated for treating diseases associated with cardiovascular targets advance toward potential approval, the market demand for high-quality oligonucleotides is anticipated to grow substantially over the next decade. Gene editing drugs are also emerging as a viable modality to treat human disease and there is a growing need for increasingly long sgRNA oligonucleotides with high purity.
The current method for oligonucleotide production relies completely on solid-phase synthesis using the phosphoramidite method and encounters challenges related to scalability, product purity, and environmental sustainability.
Chemoenzymatic ligation technology offers the promise of improved purity, yield, and environmental sustainability. It is particularly well-suited for large-scale production of siRNA and high-purity synthesis of sgRNA, making it an optimal solution for meeting future market demands.
In this video, our CTO David Butler, explores the challenges and ongoing innovation in scaling oligonucleotide production to meet an expected exponential growth in demand for RNA therapeutics over the next decade, focusing on ligation technology applied to siRNA and long sgRNA molecules.
